Eli Lilly and Co. (LLY:Quote) said Friday that the U.S. Food and Drug Administration has approved a supplemental new drug application, or sNDA, for Tradjenta tablets for use as add-on therapy to insulin.
eHealthcare Solutions (EHS) manages advertising on this website.
We use cookies to ensure that we give you the best experience on our website.
By continuing, you agree to the use of cookies as per the EHS Privacy Policy